Immunic(IMUX.US)

Last Updated 19:00:00 ET
longbridge loading

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis | IMUX Stock News

StockTitan·
US
IMUX
+1.66%
US
IXJ
+1.16%
US
FBT
+2.23%
StockTitan·
US
IMUX
+1.66%
US
IXJ
+1.16%
US
FBT
+2.23%

Immunic Appoints New CEO to Lead MS Strategy

Tip Ranks·
US
IMUX
+1.66%
US
IBB
+1.46%
US
VHT
+1.44%
Tip Ranks·
US
IMUX
+1.66%
US
IBB
+1.46%
US
VHT
+1.44%

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer | IMUX Stock News

StockTitan·
US
IMUX
+1.66%
US
FBT
+2.23%
US
ARKG
+1.24%
StockTitan·
US
IMUX
+1.66%
US
FBT
+2.23%
US
ARKG
+1.24%

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors | IMUX Stock News

StockTitan·
US
IMUX
+1.66%
StockTitan·
US
IMUX
+1.66%
© 2026 Longbridge｜Disclaimer